IRIS UniCatt

Rocca, Bianca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.247
NA - Nord America 3.978
AS - Asia 1.828
SA - Sud America 246
AF - Africa 70
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 3
Totale 10.402
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.931
DE - Germania 1.202
SE - Svezia 783
SG - Singapore 717
CN - Cina 613
IT - Italia 528
UA - Ucraina 505
IE - Irlanda 282
FR - Francia 271
BR - Brasile 188
ID - Indonesia 167
GB - Regno Unito 133
FI - Finlandia 125
PL - Polonia 113
IN - India 105
RU - Federazione Russa 104
TR - Turchia 74
BE - Belgio 35
ES - Italia 32
AU - Australia 28
HK - Hong Kong 28
IR - Iran 26
NL - Olanda 26
CA - Canada 25
CZ - Repubblica Ceca 25
AR - Argentina 23
CI - Costa d'Avorio 23
JP - Giappone 21
AT - Austria 17
MX - Messico 17
CH - Svizzera 14
ET - Etiopia 14
KR - Corea 13
CO - Colombia 11
PH - Filippine 8
CL - Cile 7
EG - Egitto 7
IL - Israele 7
ZA - Sudafrica 7
LV - Lettonia 6
MK - Macedonia 6
NO - Norvegia 6
PE - Perù 6
GR - Grecia 5
IQ - Iraq 5
NG - Nigeria 5
TW - Taiwan 5
BG - Bulgaria 4
BO - Bolivia 4
DK - Danimarca 4
EC - Ecuador 4
GH - Ghana 4
PK - Pakistan 4
PT - Portogallo 4
RO - Romania 4
SA - Arabia Saudita 4
VN - Vietnam 4
AZ - Azerbaigian 3
HU - Ungheria 3
KE - Kenya 3
LT - Lituania 3
MA - Marocco 3
MT - Malta 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
BJ - Benin 2
KW - Kuwait 2
LA - Repubblica Popolare Democratica del Laos 2
NZ - Nuova Zelanda 2
QA - Qatar 2
YE - Yemen 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AM - Armenia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
EU - Europa 1
GT - Guatemala 1
HN - Honduras 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SN - Senegal 1
TH - Thailandia 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.402
Salva come PNG Salva come JPEG
Città #
Chandler 658
Ashburn 476
Singapore 366
Dublin 276
Jacksonville 255
San Mateo 225
Jakarta 165
Wilmington 163
Nanjing 152
Woodbridge 120
Ann Arbor 106
Warsaw 105
Houston 93
Lawrence 92
Milan 91
Cattolica 88
Rome 87
Boston 80
Beijing 71
Dearborn 71
Fairfield 70
Moscow 66
New York 63
Nürnberg 59
Redwood City 59
Los Angeles 58
Seattle 54
Princeton 53
Izmir 47
Chicago 40
Nanchang 38
Munich 35
Mountain View 32
Shenyang 32
Tianjin 30
Brussels 27
University Park 26
Boardman 25
Redmond 25
Hangzhou 24
Hebei 24
Zhengzhou 24
Abidjan 23
Bremen 23
Brno 22
Hong Kong 22
Kunming 22
Nuremberg 22
Helsinki 20
Pune 20
Detroit 19
Shanghai 19
Hyderabad 18
Bareggio 17
Cambridge 17
Federal 16
Frankfurt am Main 16
Hounslow 16
Mexico 16
Tobarra 16
Wayne 16
Busto Arsizio 15
Fremont 15
Leawood 15
Marseille 15
Augusta 14
Guangzhou 14
Norwalk 14
Washington 13
Jiaxing 12
London 11
São Paulo 11
Vienna 11
Belo Horizonte 10
Düsseldorf 10
Lancaster 10
Simi Valley 10
The Dalles 10
Andover 9
Changsha 9
Falls Church 9
Ottawa 9
Paris 9
Lanzhou 8
Bursa 7
Edinburgh 7
Quezon City 7
Araucária 6
Ardabil 6
Bogotá 6
Cape Town 6
Florence 6
Hefei 6
Kish 6
Kraków 6
Latham 6
Padova 6
Prilep 6
Toronto 6
Vimercate 6
Totale 5.373
Salva come PNG Salva come JPEG
Nome #
Qualitative and quantitative modifications of von willebrand factor in patients with essential thrombocythemia and controlled platelet count 273
More, more, more: Reducing thrombosis in acute coronary syndromes beyond dual antiplatelet therapy-current data and future directions 252
Association of congenital protein C deficiency and latent myeloproliferative disease as cause of splanchnic venous thrombosis in a 34-year-old woman 233
Mean Platelet Volume, Platelet Distribution Width, and Platelet Count in Type 2 Diabetes Mellitus, Impaired Fasting Glucose, and Metabolic Syndrome: systematic review and meta-analysis 171
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study. 152
Obesity is associated with in vivo platelet activation and impaired responsiveness to once-daily, low-dose aspirin 149
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 145
Metformin improves endothelial function in type 1 diabetic subjects: a pilot, placebo-controlled randomized study 132
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 128
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 127
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 126
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 124
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13. A new prothrombotic mechanism associated with oxidative stress 122
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 116
Abnormal megakaryopoiesis and platelet function in cyclooxygenase-2-deficient mice 115
Effect of fibrinogen concentration on the velocity of platelet aggregation. 114
Pseudo-acquired vWD in essential thrombocythemia: the role of platelets 112
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 111
2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy 107
Increased thromboxane biosynthesis in essential thrombocythemia. 106
Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis 106
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 99
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia 90
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes 90
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 89
Drug insight: aspirin resistance- fact or fashion 88
Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis "in vivo" 88
Aspirin, stroke and drug-drug interactions 87
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 87
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 85
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 85
Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: A joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 83
Fechtner syndrome: report of a third family and literature review 82
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 81
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 79
Aspirin: promise and resistance in the new millennium. 78
The future of antiplatelet therapy in cardiovascular disease 78
Homocysteinemia is inversely correlated with platelet count and inversely correlated with sE-and sP-selectin levels in females homozygous for C677T methylenetetrahydrofolate reductase 78
Another family with IGPS 77
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 76
Farmaci antipiastinici 76
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 75
Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector. 74
Inherited macrothrombocytopenia with distinctive platelet ultrastructural and functional features 74
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 72
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 71
Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: A case-control study 71
Aspirin inhibits cancer stem cells properties and growth of glioblastoma multiforme through Rb1 pathway modulation 71
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD 71
Identifying determinants of variability to tailor aspirin therapy 70
Platelet progenitors: the hidden drug target 70
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 70
Cystic fibrosis transmembrane conductance regulator (CFTR) expression in human platelets: impact on mediators and mechanisms of the inflammatory response 69
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 69
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 69
Plasma protein oxidation is associated with an increase of procoagulant markers causing an imbalance between pro- and anticoagulant pathways in healthy subjects 67
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythemia 67
Stability of urinary thromboxane A2 metabolites and adaptation of the extraction method to small urine volume 66
Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis 65
Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. 64
Determinants of the interindividual variability in response to antiplatelet drugs. 64
Familial autoimmune myasthenia gravis with different pathogenetic antibodies 63
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 63
MYH9 spectrum of autosomal-dominant giant platelet syndromes: unexpected association with fibulin-1 variant-D inactivation 62
Antithrombotic therapy in diabetes: which, when, and for how long? 62
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 61
Role of prostacyclin in the cardiovascular response to thromboxane A2 61
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 61
Circulating endothelial progenitor cells and residual in vivo thromboxane biosynthesis in low-dose aspirin-treated polycythemia vera patients 60
Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter 60
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease 60
The linkage between binding of the C-terminal domain of hirudin and amidase activity in human alpha-thrombin 59
Wiskott-Aldrich syndrome: report of an autosomal dominant variant 59
Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), Working Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, WG Thrombosis, of the European Society of Cardiology, European Primary Care Cardiology Society (EPCCS) 59
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 58
Fibrinogen-elongated gamma chain inhibits thrombin-induced platelet response, hindering the interaction with different receptors 58
Increased thromboxane metabolites excretion in liver cirrhosis. 57
Nonsteroidal antiinflammatory drugs: past, present and future 57
Farmaci Antipiastrinici 56
Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: Executive Summary of a Joint Consensus Document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, Endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) 56
Unmet clinical needs of antithrombotic treatment in Philadelphia negative myeloproliferative neoplasms 55
Autosomal dominant giant platelet syndrome: a hint of the same genetic defect as in Fetchner syndrome owing to a similar genetic linkage to chromosome 22q11-13 54
A case of coloboma in a newborn to a woman taking mycophenolate mofetil in pregnancy after kidney transplantation. 54
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 54
Pathophysiology of Thrombosis in Peripheral Artery Disease 54
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 54
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 53
LACK OF AN ASSOCIATION BETWEEN INHERITED THROMBOPHILIC RISK FACTORS AND IDIOPATIC SUDDEN SENSORINEURAL HEARING LOSS IN ITALIAN PATIENTS 53
The lifespan determinant p66sch drives obesity-induced oxidative stress, mitochondrial dysfunction and vascular inflammation 52
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 52
Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs? 52
Antithrombotic therapy in patients with acute coronary syndrome complicated by cardiogenic shock or out-of-hospital cardiac arrest: a Joint Position Paper from the European Society of Cardiology (ESC) Working Group on Thrombosis, in association with the Acute Cardiovascular Care Association (ACCA) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) 51
Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms. 50
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 50
Aspirin and Other COX-1 Inhibitors 50
genetic deletion of P66 (sch) protects against obesity induced mithocondrial dysfunction, oxidative stress and vascular inflammation 49
Increased von Willebrand factor levels in polycythemia vera and phenotypic differences with essential thrombocythemia 49
Role of Oxidative Stress in the Pathogenesis of Atherothrombotic Diseases 48
Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome 48
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA) 48
Totale 8.248
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.311
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.311
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020256 0 0 0 0 0 0 0 0 0 0 138 118
2020/20211.038 43 113 24 108 149 54 115 27 140 50 181 34
2021/20221.145 157 93 13 73 86 32 32 187 44 33 175 220
2022/20232.133 313 301 176 241 175 237 75 172 257 43 95 48
2023/20241.357 43 348 42 179 80 132 97 29 28 69 136 174
2024/20251.538 61 54 196 89 199 67 36 155 416 214 51 0
Totale 10.565